Pacira Biosciences, Inc. (PCRX)

NASDAQ: PCRX · IEX Real-Time Price · USD
63.59
0.55 (0.87%)
At close: May 20, 2022 4:00 PM
63.96
0.37 (0.58%)
After-hours:May 20, 2022 5:18 PM EDT
Market Cap2.89B
Revenue (ttm)580.50M
Net Income (ttm)38.44M
Shares Out45.44M
EPS (ttm)0.84
PE Ratio75.79
Forward PE19.88
Dividendn/a
Ex-Dividend Daten/a
Volume351,717
Open63.97
Previous Close63.04
Day's Range61.96 - 64.54
52-Week Range45.05 - 82.16
Beta0.87
AnalystsBuy
Price Target82.07 (+29.1%)
Earnings DateMay 4, 2022

About PCRX

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsula...

IndustryPharmaceuticals
IPO DateFeb 3, 2011
Employees697
Stock ExchangeNASDAQ
Ticker SymbolPCRX
Full Company Profile

Financial Performance

In 2021, PCRX's revenue was $541.53 million, an increase of 26.04% compared to the previous year's $429.65 million. Earnings were $41.98 million, a decrease of -71.15%.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is 82.07, which is an increase of 29.06% from the latest price.

Price Target
$82.07
(29.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

2 weeks ago - Zacks Investment Research

Pacira (PCRX) Q1 Earnings Miss Estimates

Pacira (PCRX) delivered earnings and revenue surprises of -13.51% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Pacira BioSciences Reports First Quarter 2022 Financial Results

-- First quarter revenue of $158 million, up 33% over prior year -- -- Strong topline performance delivers net income and significantly positive adjusted EBITDA -- -- Conference call today at 8:30 a.m. ...

2 weeks ago - GlobeNewsWire

Why Pacira (PCRX) Could Beat Earnings Estimates Again

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 weeks ago - Zacks Investment Research

3 Small-Cap Medical Stocks With Big Momentum

Now is a good time to take a closer look at these stocks.

Other symbols:CORTRGNX
3 weeks ago - The Motley Fool

Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth

Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

Here's Why Pacira (PCRX) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

1 month ago - Zacks Investment Research

Pacira BioSciences to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

TAMPA, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 21st Annual Needham Virtual Health...

1 month ago - GlobeNewsWire

Pacira (PCRX) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

2 months ago - Zacks Investment Research

Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference

TAMPA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Confere...

2 months ago - GlobeNewsWire

Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales

Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.

2 months ago - Zacks Investment Research

Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.

2 months ago - Zacks Investment Research

Pacira (PCRX) Q4 Earnings and Revenues Beat Estimates

Pacira (PCRX) delivered earnings and revenue surprises of 16.87% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results

— Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million — — More than 10 million patie...

2 months ago - GlobeNewsWire

Earnings Preview: Pacira (PCRX) Q4 Earnings Expected to Decline

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Pacira to Report 2021 Financial Results on Thursday February 24, 2022

TAMPA, Fla., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2021 financial results before the...

3 months ago - GlobeNewsWire

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022

-- EXPAREL average daily sales for January 2022 were 104% of January 2021 -- -- EXPAREL average daily sales for January 2022 were 104% of January 2021 --

3 months ago - GlobeNewsWire

Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 months ago - Zacks Investment Research

5 Reasons to Bet On These 5 Buy Ranked Stocks

PCRX, DHI, ARCB, AXS and CF balance value and growth and are therefore worth picking up.

Other symbols:ARCBAXSCFDHI
4 months ago - Zacks Investment Research

Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why

Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.

4 months ago - Zacks Investment Research

Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B

-- Provides additional operational and financial flexibility -- -- Underscores strength of forecasted earnings and operating cash flow --

5 months ago - GlobeNewsWire

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL® and iovera° of $48.0 Million for November 2021

-- EXPAREL average daily sales for November 2021 - 122% of November 2020 –

5 months ago - GlobeNewsWire

Pacira (PCRX) Down 4.5% Since Last Earnings Report: Can It Rebound?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Pacira BioSciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

TAMPA, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Piper Sandler 33rd Annual Virtual H...

5 months ago - GlobeNewsWire

Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pa...

-- Adds highly complementary ZILRETTA ® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --

6 months ago - GlobeNewsWire